Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis.
Gerratana L, Davis AA, Velimirovic M, Reduzzi C, Clifton K, Bucheit L, Hensing WL, Shah AN, Pivetta T, Dai CS, D'Amico P, Wehbe F, Medford A, Wander SA, Gradishar WJ, Behdad A, Ma CX, Puglisi F, Bardia A, Cristofanilli M. Gerratana L, et al. Among authors: medford a. JCO Precis Oncol. 2023 May;7:e2200531. doi: 10.1200/PO.22.00531. JCO Precis Oncol. 2023. PMID: 37141549 Free PMC article.
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer.
Medford AJ, Dubash TD, Juric D, Spring L, Niemierko A, Vidula N, Peppercorn J, Isakoff S, Reeves BA, LiCausi JA, Wesley B, Malvarosa G, Yuen M, Wittner BS, Lawrence MS, Iafrate AJ, Ellisen L, Moy B, Toner M, Maheswaran S, Haber DA, Bardia A. Medford AJ, et al. NPJ Precis Oncol. 2019 Jul 16;3:18. doi: 10.1038/s41698-019-0090-5. eCollection 2019. NPJ Precis Oncol. 2019. PMID: 31341951 Free PMC article.
Antibody drug conjugates for patients with breast cancer.
Medford A, Spring LM, Moy B, Bardia A. Medford A, et al. Curr Probl Cancer. 2021 Oct;45(5):100795. doi: 10.1016/j.currproblcancer.2021.100795. Epub 2021 Oct 4. Curr Probl Cancer. 2021. PMID: 34635342 Review.
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer.
Davis AA, Gerratana L, Clifton K, Medford AJ, Velimirovic M, Hensing WL, Bucheit L, Shah AN, D'Amico P, Reduzzi C, Zhang Q, Dai CS, Denault EN, Bagegni NA, Opyrchal M, Ademuyiwa FO, Bose R, Gradishar WJ, Behdad A, Ma CX, Bardia A, Cristofanilli M. Davis AA, et al. Among authors: medford aj. EBioMedicine. 2022 Dec;86:104316. doi: 10.1016/j.ebiom.2022.104316. Epub 2022 Nov 1. EBioMedicine. 2022. PMID: 36332363 Free PMC article.
Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2.
Abelman RO, Medford A, Spring L, Bardia A. Abelman RO, et al. Among authors: medford a. Cancer J. 2022 Nov-Dec 01;28(6):423-428. doi: 10.1097/PPO.0000000000000634. Cancer J. 2022. PMID: 36383904 Free PMC article. Review.
TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis.
Medford AJ, Oshry L, Boyraz B, Kiedrowski L, Menshikova S, Butusova A, Dai CS, Gogakos T, Keenan JC, Occhiogrosso RH, Ryan P, Lennerz JK, Spring LM, Moy B, Ellisen LW, Bardia A. Medford AJ, et al. Ther Adv Med Oncol. 2023 Jan 30;15:17588359231152844. doi: 10.1177/17588359231152844. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36743521 Free PMC article.
Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer.
Hensing WL, Gerratana L, Clifton K, Medford AJ, Velimirovic M, Shah AN, D'Amico P, Reduzzi C, Zhang Q, Dai CS, Denault EN, Bagegni NA, Opyrchal M, Ademuyiwa FO, Bose R, Behdad A, Ma CX, Bardia A, Cristofanilli M, Davis AA. Hensing WL, et al. Among authors: medford aj. Clin Cancer Res. 2023 Aug 15;29(16):3092-3100. doi: 10.1158/1078-0432.CCR-22-3785. Clin Cancer Res. 2023. PMID: 37265453
244 results